Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
| Expenses | ||||
| Research and development | $ 712,193 | $ 947,249 | $ 1,433,668 | $ 1,966,369 |
| General and administrative | 1,053,747 | 874,884 | 1,967,375 | 1,861,354 |
| Operating expenses | 1,765,940 | 1,822,133 | 3,401,043 | 3,827,723 |
| Other (income) loss | ||||
| Change in fair value of derivative liability | (1,261) | (1,041) | ||
| Foreign exchange loss | 2,254 | 5,097 | 1,880 | 10,935 |
| Interest income | (28,143) | (16,272) | (57,001) | (36,116) |
| Other loss (income) | (25,889) | (12,436) | (55,121) | (26,222) |
| Net loss for the period | 1,740,051 | 1,809,697 | 3,345,922 | 3,801,501 |
| Computation of basic loss per share | ||||
| Net loss for the period | 1,740,051 | 1,809,697 | 3,345,922 | 3,801,501 |
| Series B Preferred stock dividend | 2,552 | 16,190 | 4,598 | 52,275 |
| Net loss for the period attributable to common stockholders | $ 1,742,603 | $ 1,825,887 | $ 3,350,520 | $ 3,853,776 |
| Basic and fully diluted loss per share | $ 0.15 | $ 0.75 | $ 0.35 | $ 1.63 |
| Basic weighted average number of shares | 11,407,744 | 2,424,222 | 9,473,153 | 2,360,566 |